Clinical Outcomes of Rituximab Infusion Among Refractory Myasthenia Gravis Patients in the Philippines: A 10-Year Retrospective Study.

Background: Myasthenia gravis (MG) is an autoimmune disorder causing muscle weakness, with 10%-20% of cases becoming refractory to standard treatments. Rituximab, a CD20-targeting monoclonal antibody, has shown promise in refractory MG but lacks data from low- and middle-income countries (LMICs), such as the Philippines.

Methods: A retrospective, cross-sectional study was conducted in treatment-refractory MG patients in St.